Stockscreener 앱 받기
3.52
1.37%
0.055
전일 마감가:
$3.465
열려 있는:
$3.46
하루 거래량:
46,080
Relative Volume:
2.42
시가총액:
$3.29M
수익:
$61,000
순이익/손실:
$-6.17M
주가수익비율:
-6.1754
EPS:
-0.57
순현금흐름:
$-6.43M
1주 성능:
+8.75%
1개월 성능:
-12.51%
6개월 성능:
-42.60%
1년 성능:
-34.98%
1일 변동 폭
$3.12
$3.79
1주일 범위
$3.12
$3.79
52주 변동 폭
$3.12
$14.80
타이탄 파마슈티컬스 Stock (TTNP) Company Profile
명칭
Titan Pharmaceuticals Inc De
전화
(650) 244-4990
주소
400 OYSTER POINT BLVD, SAN FRANCISCO
TTNP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.56 | 3.29M | 61,000 | -6.17M | -6.43M | -8.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.73 | 105.21B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.86 | 78.48B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
634.15 | 37.55B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.94 | 31.19B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.87 | 27.43B | 3.30B | -501.07M | 1.03B | -2.1146 |
타이탄 파마슈티컬스 Stock (TTNP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-06-26 | 개시 | Maxim Group | Buy |
| 2017-11-10 | 다운그레이드 | ROTH Capital | Buy → Neutral |
타이탄 파마슈티컬스 주식(TTNP)의 최신 뉴스
KalVista Pharmaceuticals Taps Former AVEO Oncology Executive as New COO in Strategic Leadership Move - StockTitan
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
MIRA Pharmaceuticals' Novel Ketamine Drug Aces Preclinical Safety Tests, Phase I Trials Set for 2025 - StockTitan
Universe Pharmaceuticals Announces $15M Direct Offering with Warrants; Univest Securities Leading Placement - StockTitan
Fresh Tracks Therapeutics Faces Dissolution as Court Schedules Critical Delaware Hearing | FRTX Stock News - StockTitan
KalVista Pharmaceuticals Awards Inducement Stock Options to New Executive Team Members - StockTitan
Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan
X4 Pharmaceuticals Issues Major Stock Option Awards to New Employees at $0.371 Per Share - StockTitan
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV - StockTitan
Terns Pharmaceuticals Grants 150,000 Share Options to New Employee at $6.24 - StockTitan
Titan Pharmaceuticals faces Nasdaq compliance issues - Investing.com
Titan Pharmaceuticals Faces Double Nasdaq Compliance Challenge Over Filing, Audit Issues | TTNP Stock News - StockTitan
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Lexicon Pharma Cuts 60% of Workforce, Saves $140M Amid FDA Setback for Zynquista - StockTitan
Conduit Pharma Secures Key Patent for Autoimmune Drug AZD1656 in Major Japan Market | CDT Stock News - StockTitan
Lexicon Pharmaceuticals Appoints Former Eisai CEO Ivan Cheung to Board of Directors | LXRX Stock News - StockTitan
Melt Pharma's MELT-300 Shows Breakthrough Results in Phase 3 Sedation Trial | HROW Stock News - StockTitan
Napo Therapeutics Wins 'Best Pharma Innovator' Award, Advances Rare Disease Drug Trials | JAGX Stock News - StockTitan
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
Conduit Pharmaceuticals Strengthens Board with 30-Year Investment Banking Veteran Simon Fry - StockTitan
NeuroBo Pharma Rebrands as MetaVia, Advances $70M Cardiometabolic Pipeline | NRBO Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M to Advance Pain Management Drug Development | VRPX Stock News - StockTitan
Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan
TFF Pharmaceuticals Announces Complete Shutdown, Appoints Wind-Down Specialist as CEO | TFFP Stock News - StockTitan
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share - StockTitan
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan
Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates - StockTitan
CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
Citius Phase 1 Trial Shows 27% Response Rate with LYMPHIR-Keytruda Combo in Cancer Study - StockTitan
InMed Announces 1-for-20 Reverse Split to Maintain Nasdaq Listing - StockTitan
NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan
Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan
Amylyx Reports Mixed Q3: Positive Trial Data Despite $72.7M Loss, Cash Runway Into 2026 | AMLX Stock News - StockTitan
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan
InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan
Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Acadia Pharma Sells FDA Priority Review Voucher for $150M, Boosts R&D Pipeline - StockTitan
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - StockTitan
타이탄 파마슈티컬스 (TTNP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
2.37%
자본화:
|
볼륨(24시간):